[Guideline: Treatment of Adult Obstructive Sleep Apnea.]

Laryngorhinootologie. 2007 Apr 26;

Authors: Verse T, de la Chaux R, Dreher A, Fischer Y, Grundmann T, Hecksteden K, Hörmann K, Hohenhorst W, Ilgen F, Kühnel T, Mahl N, Maurer JT, Pirsig W, Roth B, Siegert R, Stuck BA

PMID: 17464894 [PubMed - as supplied by publisher]

]]>

Implementing epilepsy guidelines within a learning disability service.

Seizure. 2007 Apr 26;

Authors: Whitten E, Griffiths A

PURPOSE: To investigate the usefulness of the implementation of NICE guidelines when reviewing care within an outpatient learning disability service. METHODS: We set up a multi disciplinary specialist epilepsy clinic and reviewed all patients with a diagnosis of epilepsy using a specific assessment document based on NICE guidance. We then audited clinical documentation prior to and after the implementation of the clinic. RESULTS: We reviewed 23 patients and found that implementing NICE guidelines showed improvements to individuals’ seizure assessments and epilepsy management. When comparing specific areas related to NICE implementation we found that 83% compared to 6% of patients had accurate name and detailed seizure descriptions. We made changes to seizure diagnosis in 76% of patients and improved the level of recording of seizure frequency and severity. Finally 91% compared to 50% of consultations led to changes in treatment plans. CONCLUSION: We found that implementing the NICE guidelines allowed us to use a systematic approach to epilepsy management, which in turn led to identifiable improvement in documentation and patient care.

PMID: 17467302 [PubMed - as supplied by publisher]

]]>

The resuscitation guidelines in force-Time for improvement towards causal therapy?

Resuscitation. 2007 Apr 28;

Authors: Sloth E, Jakobsen CJ, Melsen NC, Ravn HB

PMID: 17467874 [PubMed - as supplied by publisher]

]]>

Guidelines for submitting adverse event reports for publication.

Pharmacoepidemiol Drug Saf. 2007 May 1;16(5):581-587

Authors: Kelly WN, Arellano FM, Barnes J, Bergman U, Edwards IR, Fernandez AM, Freedman SB, Goldsmith DI, Huang K, Jones JK, McLeay R, Moore N, Stather RH, Trenque T, Troutman WG, van Puijenbroek E, Williams F, Wise RP

Publication of case reports describing suspected adverse effects of drugs and medical products that include herbal and complementary medicines, vaccines, and other biologicals and devices is important for postmarketing surveillance. Publication lends credence to important signals raised in these adverse event reports. Unfortunately, deficiencies in vital information in published cases can often limit the value of such reports by failing to provide sufficient details for either (i) a differential diagnosis or provisional assessment of cause-effect association, or (ii) a reasonable pharmacological or biological explanation. Properly described, a published report of one or more adverse events can provide a useful signal of possible risks associated with the use of a drug or medical product which might warrant further exploration. A review conducted by the Task Force authors found that many major journals have minimal requirements for publishing adverse event reports, and some have none at all. Based on a literature review and our collective experience in reviewing adverse event case reports in regulatory, academic, and industry settings, we have identified information that we propose should always be considered for inclusion in a report submitted for publication. These guidelines have been endorsed by the International Society for Pharmacoepidemiology (ISPE) and the International Society of Pharmacovigilance (ISoP) and are freely available on the societies’ web sites. Their widespread distribution is encouraged. ISPE and ISoP urge biomedical journals to adopt these guidelines and apply them to case reports submitted for publication. They also encourage schools of medicine, pharmacy, and nursing to incorporate them into the relevant curricula that address the detection, evaluation, and reporting of suspected drug or other medical product adverse events. Copyright (c) 2007 Kelly et al. Reproduced with permission by John Wiley & Sons, Ltd.

PMID: 17471601 [PubMed - as supplied by publisher]

]]>